- Home
- CNTA
as 11-21-2024 4:00pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 2.2B | IPO Year: | 2021 |
| Target Price: | $23.71 | AVG Volume (30 days): | 527.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.58 - $18.74 | Next Earning Date: | 11-12-2024 |
| Revenue: | $6,853,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SAHA SAURABH | CNTA | Chief Executive Officer | Nov 13 '24 | Sell | $18.28 | 32,023 | $585,418.87 | 630,661 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Oct 25 '24 | Sell | $15.38 | 11,742 | $180,628.36 | 183,266 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Oct 21 '24 | Sell | $15.59 | 55,000 | $863,727.20 | 630,661 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Sep 25 '24 | Sell | $15.69 | 16,619 | $260,723.86 | 183,266 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Sep 20 '24 | Sell | $16.53 | 55,000 | $908,985.00 | 630,661 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Sep 10 '24 | Sell | $17.00 | 30,000 | $510,000.00 | 183,266 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Sep 9 '24 | Sell | $15.00 | 25,000 | $375,000.00 | 183,266 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Morgan Stanley Lifts Price Target on Centessa Pharmaceuticals to $27 From $26, Keeps Overweight Rating
BioPharma Dive
9 days ago
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
MT Newswires
10 days ago
Centessa Pharmaceuticals' Q3 Loss Widens
GlobeNewswire
10 days ago
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
GlobeNewswire
18 days ago
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
MT Newswires
a month ago
Centessa Pharmaceuticals Insider Sold Shares Worth $863,727, According to a Recent SEC Filing
Insider Monkey
a month ago
Centessa Pharmaceuticals Plc (CNTA): A Small-Cap Leader in Clinical-Stage Biotech
Insider Monkey
a month ago
Analysts Rate Centessa Pharmaceuticals Plc (CNTA) as Strong Buy Amid Promising Developments
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.